ZyVersa

ZyVersa is a clinical-stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop product candidates addressing significant unmet medical needs in the renal and inflammatory disease spaces. ZyVersa's development pipeline includes VAR 200, which is ready for Phase 2a trials, a cholesterol efflux mediator for treating the rare kidney disease focal segmental glomerulosclerosis (FSGS). ZyVersa believes VAR 200 has the potential to treat other glomerular diseases, including Alport syndrome and diabetic nephropathy. ZyVersa’s development pipeline also includes IC 100, a novel inflammasome ASC inhibitor.